Discuss the recent progress on the clinical use of mesenchymal stromal (stem) cells (MSC) in solid organ transplantation (SOT).
INTRODUCTION
Transplanting cells, tissues and organs aims at the long-lasting restoration of function lost to genetic defect, inflammation, toxicity or trauma. Cellular therapies are emerging as therapeutic options to ameliorate, reduce, modify, correct and cure medical conditions. Mesenchymal stromal (stem) cells (MSC) are particularly appealing because of their tissue repair and immunomodulatory potential [1] . Herein, we review and discuss the recent progress on the clinical use of MSC in solid organ transplantation (SOT) [ 
RATIONALE FOR THE USE OF MESENCHYMAL STROMAL (STEM) CELLS IN SOLID ORGAN TRANSPLANTATION
Mesenchymal stromal (stem) cells comprise a heterogeneous cell population of putative perycytic origin [11] [12] [13] . The 2006 guidelines of the International Society for Cellular Therapy (ISCT) identify MSCs based on adherence to plastic; at least 95% of the MSC population must express CD105, CD73 and CD90; must lack expression 2% or less positive of CD45, CD34, CD14 or CD11b, CD79a or CD19 and human leukocyte antigen (HLA) class II); and multipotent differentiation (osteoblast, adipocyte and chondroblast under standard in vitro differentiating conditions) [12] . Bona-fide MSCs are obtained from bone marrow, adipose tissue, umbilical cord, and other human tissues [14,15,16 && ,17] , likely because of their perivascular (pericyte) origin [18] [19] [20] .
Autologous MSCs are obtained from the patient's own tissues or from HLA-identical siblings. Allogeneic MSCs are obtained from 'donor-specific' (if also donate the solid organ) or 'third-party' HLA-matched/mismatched individuals ( Fig. 1 ). Mesenchymal stromal (stem) cells are obtained in adequate numbers prior to transplantation from either a prospective living donor or from the recipient and used fresh or cryopreserved.
Third-party (off-the-shelf) allogeneic MSCs may represent a practical choice if other options are unavailable.
Ischemia-reperfusion injury (IRI) of SOT is the result of hypoxia-mediated cellular death and activation of stress-induced signal transduction pathways in vascular endothelium and organ parenchyma, which are triggered by cerebral or cardiac death and organ preservation, and are further amplified after reperfusion. Consequences of IRI include delayed function and primary nonfunction, heightened organ immunogenicity because of increased expression of major histocompatibility complex molecules, proinflammatory mediators and activation of adaptive immunity. In fact, deceased donor organs have higher rates of rejection than living-donor organs [21, 22] .
After inoculum, MSCs preferentially home at the site of vascular damage or inflammation wherein they likely function as the native resident pericytes/MSCs do in small, minor injuries [23, 24] . This property may help mitigating IRI [25, 26] , rescuing marginal donor organs, reducing activation of innate immunity leading to progressive tissue fibrosis and blunting 'danger signals' that could synergize with immune tolerance-inducing strategies ( Table 1) .
Immunosuppressive protocols generally combine agents, including lymphodepletion [i.e., rabbit antilymphocyte globulin (RATG), anti-CD25 antibody (targeting the interleukin-2 receptor), anti-CD52 antibody (campath-1H, alemtuzumab), anti-CD3 antibody, among others], calcineurin inhibitors (CNI: cyclosporine A, CsA; and tacrolimus), molecular target of rapamycin (mTOR) inhibitors (sirolimus and everolimus), purine/pyrimidine synthesis inhibitors (mycophenolate mofetil -MMF; mycophenolic Tissue repair and immunomodulatory properties have  been recognized for MSCs obtained from different  human tissues. MSC-based therapy has been proposed to reduce IRI, reduce immunosuppression, treat rejection episodes and possibly induce immune tolerance.
KEY POINTS
Initial clinical reports support the safety of MSCs in SOT and reveal encouraging positive effects on engraftment, reduction of immunosuppression burden, reduction of rejection and possibly inducing immune modulation.
MSCs may represent a viable adjuvant therapy to improve clinical outcomes in SOT. acid -MPA; azathioprine -AZA), cyclophosphamide (CyP) and/or steroids, among others. Immunosuppression heightens the risk of opportunistic infections and organ toxicity (which may progress to end-stage failure) [27, 28] , and may affect quality of life of transplanted patients, as well as graft survival. Achieving permanent acceptance of transplanted tissues reproducibly without the need for life-long antirejection therapy represents the 'Holy Grail' of transplant immunobiology, and has been reported only sporadically or in limited patient cohorts [29] [30] [31] [32] [33] [34] . Immunomodulatory effects of MSCs have been recognized on T-cell, B-cell, natural killer cell, dendritic cell and monocyte functions, as well as on the induction of 'regulatory' immune circuits [35,36,37 & ,38]. Bartholomew et al. [35] described the immunomodulatory properties of MSCs in allogeneic nonhuman primate skin grafts. Le Blanc et al. [39, 40] demonstrated that bone marrow-MSC (BM-MSC) administration, irrespective of the HLA matching of the MSC donors, effectively treats severe graft-versus-host disease refractory to steroids in hematopoietic stem cell (HSC) transplant recipients. Thus, in SOT, MSC treatment may help reducing the burden of immunosuppressive regimen, treat rejection episodes and promote induction of immune tolerance ( (Table 3) .
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Vanikar et al. [2] first reported the use of donor-specific adipose tissue-MSC (AT-MSC) as part of a nonrandomized protocol aimed at the induction of donor hyporesponsiveness in 100 recipients of living donor kidney transplantation (LDKT) for end-stage renal disease (ESRD). Treatment included donor-specific leukocyte transfusion (day À27, day À25); anti-CD20 antibody (Rituximab; 6 mg/kg, day À18; RATG (1.5 mg/kg, day À17); unmodified donor-marrow HSC (200 ml, day À16); nonmyeloablative conditioning with total body irradiation (targeted to subdiaphragmatic lymph nodes, spleen, pelvic bones and lumbar vertebrae; 200 CGy Â 5 days); intraportal infusion of donor-specific AT-MSC, 10-day cultured bone marrow cells, and peripheral blood stem cells (G-CSF mobilization in the prospective donor; day À9); methylprednisone (500 mg i.v., days À1, 0, þ1); CNI (CsA 3 mg/kg/day) and prednisone (20 mg/day) for first trimester, then AZA and prednisone (5-10 mg/day). Controls (n ¼ 100) received the same treatment without AT-MSC. The AT-MSC group displayed improved graft survival, sustained hematopoietic chimerism levels using low-dose immunosuppression than controls over an 18-month follow-up period. Similar outcomes over a 4-year period were observed in a subsequent large-scale, nonrandomized LDKT trial (patients declining HSC/MSC protocol enrolled as controls) [4 & ] testing the induction of hyporesponsiveness protocol with donor-specific AT-MSC in 606 patients vs. 310 controls receiving conventional triple immunosuppression. The results of the study are promising, although lack of randomization in both studies, and lack of a group of patients receiving the conditioning without AT-MSC in the latter limits the generalization of the results.
Perico et al. [3] tested autologous BM-MSC in two patients with ESRD receiving LDKT. One week after LDKT, intravenous (i.v.) BM-MSC (1.7-2.0 Â 10 6 /kg body weight) was given under conventional immunosuppression with fractioned RATG (0.5 mg/kg, days 0 through 6), anti-CD25 antibody (basiliximab, 20 mg i.v. pretransplant and day 4), steroids (tapered and weaned by 1-week posttransplant) and CNI (CsA) and MMF maintenance. Transient increase in serum creatinine that was treated with steroids was observed in both patients, who displayed good graft function at 1 year. Increased frequency of CD4 þ CD25 high FoxP3 þ CD127 À T-regulatory (Treg) cells and reduction of CD8 þ CD45RO þ RA T-memory cells were observed in these two patients, when compared with historical controls receiving the same immunosuppression without MSCs. A subsequent pilot trial on two additional patients evaluated the impact of timing of autologous BM-MSC inoculum and the omission of CD25 blockade from standard immunosuppression [10 & ]. Intravenous BM-MSC (2.0 Â 10 6 /kg BW) was given on the day before LKDT. One patient with higher HLA haplotype mismatch developed transient elevation of serum creatinine 2-weeks after transplant with histopathology-compatible with acute cellular rejection (ACR) that resolved after steroid pulses. In-vitro CD8 þ T-cell cytolytic function appeared more suppressed to donor than to the third-party antigens in both MSC recipients; response to donor antigens progressively returned to baseline, whereas response to third-party antigens was unaffected by immunosuppression in historical controls by 12 months. T-memory/effector-cell proportions in historical controls with standard immunosuppression (and anti-CD25 antibody) increased over time, but markedly decreased by day 7 and remained lower than pretransplant throughout the 1-year follow-up in both MSC recipients. Unlike their previous trial [3] , Treg proportions appeared unaffected by MSC inoculum, except for a transient decreased soon after transplantation [10 & ]. These two pilot trials preliminary confirmed safety and provided encouraging mechanistic observations after inoculum of autologous MSCs in immunosuppressed SOT recipients (Table 3) , although small sample size, lack of concomitant controls and of randomization limit generalizations.
Tan et al. received anti-CD25 antibody and standard dose CNI (either CsA or tacrolimus). In the two experimental arms, anti-CD25 treatment was replaced by BM-MSC inoculum (1-2 Â 10 6 /kg i.v. at reperfusion and day 14 posttransplant) with either standard (n ¼ 52) or reduced-dose CNI (80% of standard dose; n ¼ 52), the latter to prevent organ toxicity [41, 42] . The primary outcome was 1-year incidence of biopsy-confirmed ACR and estimated glomerular filtration rate. The secondary outcome was 1-year patient and graft survival and incidence of adverse events. Replacement of CD25 blockade with autologous MSCs in LDKT transplant recipients did not compromise graft and patient safety while yielding, when compared with controls, faster recovery of renal graft function during the first month posttransplant (suggesting a possible effect on IRI, a recognized risk factor for graft failure and ACR) [43, 44] ; lower frequency of and less severe biopsyconfirmed ACR in the first semester posttransplant (none steroid-resistant requiring RATG, vs. 7.8% in the controls); and fewer adverse events, particularly opportunistic infections. One-year graft function was comparable in all groups. Similar graft survival rates with the reduction of maintenance CNI therapy in LDKT recipients was previously reported only in recipients of whole or fractionated donorspecific bone marrow cell transplantation [45] or using anti-CD52 antibody lymphodepletion (in the absence of cellular therapy), although the latter increased the rates of severe opportunistic infections [46] . Notably, opportunistic infections occurring mostly in the first two trimesters heighten mortality rates in kidney transplant recipients in China [47] . Secretion by MSCs of antimicrobial/ immunomodulatory molecules (i.e., cathelicidin hCAP-18/LL-37) [48] might have contributed, at least in part, to the significantly lower rates of opportunistic infections in recipients of MSC, and low and standard CNI doses in our trial.
Peng et al. 
CONSIDERATIONS REGARDING THE CLINICAL USE OF MESENCHYMAL STROMAL (STEM) CELLS IN SOLID ORGAN TRANSPLANTATION
The methods utilized for MSC isolation (i.e., enzymatic vs. nonenzymatic), selection (i.e., adherence to plastic, cell sorting based on surface cell markers, etc.), expansion (i.e., culture media and supplements, oxygen tension, etc.), and assessment are not yet fully standardized among facilities and based on the anatomical source [16 && ]. Since the 2006 ISCT guidelines [12] , improved criteria for MSC isolation and characterization have been proposed [49 & ,50,51 & ]. It remains to be elucidated whether comorbidities (i.e., chronic medical conditions: diabetes, ESRD, etc.) of MSC donor and/or recipient may negatively affect efficacy and potency of the cellular products [52] , and whether these effects can be reverted under the appropriate conditions (i.e., in-vitro culture and/or in-vivo treatments) [53-55, 56 & ,57]. Multipotency and immunomodulatory properties of MSCs may represent, at least hypothetically, a safety threat for transplant recipients who are immunosuppressed. Development of MSC-derived neoplasm is possible, although never reported in relation to MSC inoculum in humans. A meta-analysis on a sample of 1,012 MSC recipients confirmed clinical safety [58 && ], even though heterogeneity of both the medical conditions and protocols analyzed should suggest caution. Potentiation of immunosuppression by MSCs may heighten risk of (de-novo and/or reactivation) viral infections, lymphoproliferative diseases and progressive multifocal leukoencephalopathy. Common practice prophylaxis, close monitoring and careful assessment of immune and viral status of the recipients could allow for timely interventions aimed at minimizing risks.
The effects (synergy or competition) of concomitant therapy on MSC viability, potency and efficacy are being investigated. Preliminary studies suggest that CNIs and of mTOR inhibitors, but not purine/pyrimidine synthesis inhibitors (MMF and MPA), may interfere with the immunomodulatory properties of MSCs [3, [59] [60] [61] [62] . RATG binds to human MSC in a dose-dependent fashion in vitro [3,63 & ] and this phenomenon is associated with MSC death, impaired in-vitro immunosuppressive effects, and susceptibility to lysis by cytokine-activated CD8 þ cytotoxic cells and natural killer cells [63 & ]. Human MSCs exposed to serum collected from renal transplant recipients who had received RATG treatment displayed only minimal RATG binding with no impairment of in-vitro MSC immunomodulatory effects in mixed lymphocyte reactions [3] ; addition of CsA, MMF or steroids to the cultures did interfere with MSC suppression of T-cell responses to mitogenic stimulation with anti-CD3/CD28 antibodies in vitro, whereas synergy was rather observed with MMF [3] .
The immunogenicity of transplanted MSCs (donor-specific or third-party) may negatively impact SOT survival. Griffin et al. [64 && ] collected literature evidence in support of specific cellular (T-cell-mediated) and humoral (involvement of B-cell/antibody) immune responses against donor antigens following the administration of nonmanipulated, interferon-g-activated and differentiated allogeneic MSC. These important aspects deserve further studies in the clinical setting.
Although the overall safety of MSC therapies emerges from recent clinical SOT trials, the heterogeneity in the design (MSC source, route and schedule of administration, concomitant immunotherapy and study endpoints) among the published clinical trials limits the possibility of meaningful comparisons at the present time.
For a widespread application of clinical MSC products, 'regional' (centralized) cell processing facilities or the use of off-the-shelf, 'standardized' MSC products (i.e., centralized or industry manufacturing) may allow containing the costs. The remarkable financial burden imposed by the regulatory framework requiring proof safety and efficacy of cellular therapies under the Investigational New Drug classification before a Biological License is obtained from regulatory agencies represents an important hurdle to the transition of cellular therapies from academic initiatives into widespread clinical applications. This issue has provoked an intense debate, as elevated costs may hinder the development of potentially promising cellular therapies that could benefit humankind even beyond SOT [65 & ]. Patients' safety is paramount. Clinical studies should be performed under ethically approved protocols and appropriate Data Safety Monitoring Board oversight. Establishment of a 'Cell Therapy in SOT' Registry to gather critical parameters and outcomes will be of assistance in assessing the safety and efficacy of MSC therapy in SOT and guide the design of future trials. The selection of 'standardized' tests (i.e., cell product identity, potency and clinical outcomes) and endpoints to be adopted across centers would further promote the progress of the field.
CONCLUSION
We are living in very exciting times with the implementation of novel clinical trials aimed at establishing safety, feasibility and efficacy of cellular therapies and MSCs to improve SOT outcomes. The results of the initial clinical trials are quite promising, supporting the safety of the procedure and beneficial effects on SOT and justifying cautious optimism for the immediate future.
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